ExodusPoint Capital Management’s Autolus Therapeutics AUTL Stock Holding History

ExodusPoint Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-251,361	Closed	-$1.62M	–	1478
2023 Q4	$1.62M	Sell	251,361 -458,994	-65%	-$1.75M	0.01%	647
2023 Q3	$1.66M	Sell	710,355 -67,405	-9%	-$192K	0.02%	742
2023 Q2	$1.85M	Buy	777,760 +363,996	+88%	+$864K	0.02%	838
2023 Q1	$761K	Buy	413,764 +72,044	+21%	+$141K	0.01%	1225
2022 Q4	$649K	Buy	341,720 +137,404	+67%	+$347K	0.01%	1093
2022 Q3	$437K	Buy	204,316 +55,281	+37%	+$164K	0.01%	1415
2022 Q2	$422K	Buy	+149,035	New	+$454K	0.01%	1421

Other funds holding AUTL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ExodusPoint Capital Management's AUTL Position: Q1 2024 in Review

ExodusPoint Capital Management sold out of Autolus Therapeutics (AUTL) in Q1 2024, closing a stake of 251,361 shares — an estimated $1.62M sold.

ExodusPoint Capital Management first reported a position in AUTL in Q2 2022 and held it in 7 quarters. The position peaked at $1.85M in Q2 2023. 121 funds tracked by Wall St. Rank hold AUTL as of Q1 2024.

ExodusPoint Capital Management reported no remaining Autolus Therapeutics position as of Q1 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 251,361 Autolus Therapeutics shares in Q1 2024, an estimated $1.62M.
ExodusPoint Capital Management first reported a position in Autolus Therapeutics in Q2 2022 and held it in 7 quarters.
ExodusPoint Capital Management's Autolus Therapeutics position peaked at $1.85M in Q2 2023.
121 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2024.

Based on ExodusPoint Capital Management's 13F filing for Q1 2024, filed 14 May 2024.